Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OS ...

Sebi has approved new disclosure standards for Related Party Transactions to boost transparency and investor protection. The ...

Supermarkets will have aisles full of foods for the elderly, as well as the usual baby pouches and snacks. Your chocolate won’t come from cocoa at all, but from broad bean plants. These are some of ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Instead, the stock's ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

Kilroy Realty has opened a second phase of its Oyster Point life sciences campus — but it's attracting financial and tech ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

The Bengaluru-based firm’s initial public offering, valued at ₹1,269 crore, is set to close on February 12. The firm has ...